Synmosa Biopharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Synmosa Biopharma hat ein Gesamteigenkapital von NT$8.2B und eine Gesamtverschuldung von NT$2.4B, wodurch sich der Verschuldungsgrad auf 29.6% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen NT$12.1B bzw. NT$3.9B. Synmosa Biopharma Das EBIT des Unternehmens beträgt NT$668.2M, so dass der Zinsdeckungsgrad 16.5 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von NT$1.8B.

Wichtige Informationen

29.6%

Verhältnis von Schulden zu Eigenkapital

NT$2.43b

Verschuldung

Zinsdeckungsgrad	16.5x
Bargeld	NT$1.83b
Eigenkapital	NT$8.22b
Gesamtverbindlichkeiten	NT$3.85b
Gesamtvermögen	NT$12.07b

Jüngste Berichte zur Finanzlage

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 4114Die kurzfristigen Aktiva des Unternehmens (NT$4.8B) übersteigen seine kurzfristigen Passiva (NT$2.2B).

Langfristige Verbindlichkeiten: 4114Die kurzfristigen Vermögenswerte des Unternehmens (NT$4.8B) übersteigen seine langfristigen Verbindlichkeiten (NT$1.7B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 4114Die Nettoverschuldung im Verhältnis zum Eigenkapital (7.3%) wird als zufriedenstellend angesehen.

Schulden abbauen: 4114 Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 73.7% auf 29.6% zurückgegangen.

Schuldendeckung: 4114Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (21.9%).

Zinsdeckung: 4114Die Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (16.5x Coverage) gut gedeckt.

Synmosa Biopharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.53 (vs NT$0.42 in 2Q 2023)

Synmosa Biopharma Corporation to Report Q2, 2024 Results on Aug 13, 2024

Dividend of NT$0.60 announced

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 13, 2024

First quarter 2024 earnings released: EPS: NT$0.48 (vs NT$0.35 in 1Q 2023)

Synmosa Biopharma Corporation to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$1.61 (vs NT$2.25 in FY 2022)

Synmosa Biopharma Corporation, Annual General Meeting, May 30, 2024

Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee

Third quarter 2023 earnings released: EPS: NT$0.35 (vs NT$0.32 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: NT$0.46 (vs NT$1.13 in 2Q 2022)

Upcoming dividend of NT$0.56 per share at 1.4% yield

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 15, 2023

Synmosa Biopharma Corporation Appoints Tu, San-Chien as Additional Independent Director

New minor risk - Shareholder dilution

Synmosa Biopharma Corporation announced that it expects to receive TWD 950 million in funding

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.24 (vs NT$0.23 in 2Q 2021)

Upcoming dividend of NT$0.51 per share

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Announces Changes to the Compensation Committee

First quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.20 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.02 (vs NT$2.20 in FY 2020)

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2022

Third quarter 2021 earnings released: EPS NT$0.24 (vs NT$0.25 in 3Q 2020)

Upcoming dividend of NT$0.30 per share

Second quarter 2021 earnings released: EPS NT$0.29 (vs NT$1.66 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.23 (vs NT$0.26 in 1Q 2020)

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Synmosa Biopharma Corporation Approves Cash Dividends

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2021

Full year 2020 earnings released: EPS NT$2.46 (vs NT$0.20 in FY 2019)

Revenue beats expectations

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$24.05

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day high - NT$27.60

Price target raised to NT$28.00

New 90-day high - NT$26.95

First half earnings released

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen